Status:
COMPLETED
Airflow Obstruction and Biomarkers of Airway Inflammation During and Following Acute Exacerbations of Childhood Asthma
Lead Sponsor:
Seattle Children's Hospital
Collaborating Sponsors:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
6-18 years
Brief Summary
This study is a longitudinal single-center pilot study designed to describe changes in lung function and levels of noninvasive biomarkers of airway inflammation in children ages 6-18 years over two mo...
Eligibility Criteria
Inclusion
- Asthma Group
- At least a one-year history of physician diagnosed asthma
- Enrollment within 48 hours of hospitalization, and prior to hospital discharge, for an acute asthma exacerbation.
- Age 6 - 18 years.
- Birth at ≥ 36 weeks gestation.
- Ability to perform acceptable and reproducible spirometry meeting American Thoracic Society guidelines.
- Control Group
- Age 6 - 18 years.
- No prior history of asthma.
- Birth at ≥ 36 weeks gestation.
- Ability to perform acceptable and reproducible spirometry meeting American Thoracic Society guidelines.
Exclusion
- Asthma Group
- History of daily oral steroid use during the month before treatment for the current exacerbation.
- Use of a leukotriene antagonist.
- Birth at ≥ 36 weeks gestation.
- Control Group
- History of asthma or reactive airway disease.
- History of a prior illness with wheezing.
- History of chronic cough (daily over the month prior to enrollment).
- History of allergic rhinitis.
- History of atopic dermatitis.
- History of food allergies.
- A URI or episode of sinusitis within 3 weeks of study entry.
Key Trial Info
Start Date :
January 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01227070
Start Date
January 1 2006
End Date
March 1 2010
Last Update
October 22 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seattle Children's Hospital
Seattle, Washington, United States, 98115